Is there an interaction between famotidine and cabergoline or atorvastatin?

Does famotidine change how cabergoline works?
Famotidine is a weak, minimally metabolized H₂‑receptor blocker that is largely excreted unchanged in the urine. Cabergoline is a dopamine agonist cleared mainly by the liver via CYP3A4. Because famotidine neither induces nor inhibits CYP enzymes, it does not alter cabergoline’s pharmacokinetics or effectiveness. Patients can take the two drugs together without dose adjustments.

Can famotidine affect atorvastatin levels or side‑effects?
Atorvastatin is metabolized by CYP3A4, and its absorption can be reduced by acidic gastric pH. Famotidine raises gastric pH, but the increase is modest compared with proton‑pump inhibitors. Clinical studies have not shown a meaningful change in atorvastatin exposure or in the incidence of myopathy or liver enzyme elevation when famotidine is co‑administered. Standard dosing can continue unchanged.

Are there any safety signals when the three drugs are combined?
No major adverse interactions have been reported in the literature or in FDA prescribing information. The only potential concern is the cumulative effect of reduced gastric acidity on the absorption of other medications that are pH‑dependent, but atorvastatin’s absorption is relatively pH‑insensitive, and cabergoline’s absorption is not significantly influenced by gastric pH.

What do the drug labels say?
The famotidine label lists “no clinically significant interactions” with either cabergoline or atorvastatin. The cabergoline label notes that it is not a substrate, inhibitor, or inducer of CYP3A4, so it does not interact with CYP3A4‑metabolized drugs like atorvastatin. Atorvastatin’s label lists only acid‑suppressing agents that significantly increase gastric pH (e.g., omeprazole) as having a potential effect on its absorption; famotidine’s effect is minimal.

Should patients monitor for any specific side effects?
Because famotidine is unlikely to alter the action of cabergoline or atorvastatin, routine monitoring beyond the usual precautions for each drug is adequate. Report any new or worsening symptoms—such as muscle pain, elevated liver enzymes, or gastrointestinal issues—to a healthcare provider.

When might a clinician consider an alternative acid blocker?
If a patient requires stronger acid suppression (e.g., severe reflux or ulcers) while taking cabergoline or atorvastatin, a proton‑pump inhibitor may be chosen, but the clinician should weigh the modest risk of reduced atorvastatin absorption against the benefits of stronger acid control.

Key Takeaway
Famotidine does not meaningfully interact with cabergoline or atorvastatin. Both can be used together without dose changes, and routine safety monitoring applies to each drug separately.